EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application of an NMR/Crystallography Fragment Screening Platform for the Assessment and Rapid Discovery of New HIV‐CA Binding Fragments

Stuart Lang, Daniel A Fletcher, Alain-Pierre Petit iD, Nicola Luise, Paul Fyfe iD, Fabio Zuccotto iD, David Porter, Anthony Hope, Fiona Bellany iD, Catrina Kerr, Claire J Mackenzie iD, Paul G Wyatt iD und 1 weitere

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Stuart Lang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cresset Discovery, New Cambridge House, Bassingbourn Road, Litlington, Cambridgeshire, SG80SSS. Hauptthemen laut MEDLINE: Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identification and assessment of novel targets is essential to combat drug resistance in the treatment of HIV/AIDS. HIV Capsid (HIV‐CA), the protein playing a major role in both the early and late stages of the viral life cycle, has emerged as an important target. We have applied an NMR fragment screening platform and identified molecules that bind to the N ‐terminal domain (NTD) of HIV‐CA at a site close to the interface with the C ‐terminal domain (CTD). Using X‐ray crystallography, we have been able to obtain crystal structures to identify the binding mode of these compounds. This allowed for rapid progression of the initial, weak binding, fragment starting points to compounds 37 and 38 , which have 19 F‐pK i values of 5.3 and 5.4 respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsCrystallography, X-RayBinding SitesDrug DiscoveryHIV-1Protein BindingCapsid ProteinsHumansMolecular StructureModels, MolecularMagnetic Resonance SpectroscopyStructure-Activity Relationship

Substanzen

Anti-HIV AgentsCapsid Proteins

Autor:innen und Institutionen

  • Cresset Discovery, New Cambridge House, Bassingbourn Road, Litlington, Cambridgeshire, SG80SSS.
  • BioAscent Discovery Ltd, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH.
  • Drug Discovery Unit, University of Dundee, Dow Street, Dundee, DD1 5EH.
  • Alira Health, Av. De Josep Tarradellas, 123, 7th Floor, 08029, Barcelona, Spain.
  • Vertex Pharmaceuticals (Europe) Ltd, 86-88, Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RW.
  • Evotec (UK) Ltd, Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ.

ORCID-Profile: Alain-Pierre Petit, Paul Fyfe, Fabio Zuccotto, Fiona Bellany, Claire J Mackenzie, Paul G Wyatt, David W Gray

Förderung

  • Medical Research Council

Zitieren

APA

Lang, S., Fletcher, D. A., Petit, A. P., Luise, N., Fyfe, P., Zuccotto, F., Porter, D., Hope, A., Bellany, F., Kerr, C., Mackenzie, C. J., Wyatt, P. G., & Gray, D. W. (2024). Application of an NMR/Crystallography Fragment Screening Platform for the Assessment and Rapid Discovery of New HIV‐CA Binding Fragments. ChemMedChem. https://doi.org/10.1002/cmdc.202400025

Vancouver

Lang S, Fletcher DA, Petit AP, Luise N, Fyfe P, Zuccotto F, et al. Application of an NMR/Crystallography Fragment Screening Platform for the Assessment and Rapid Discovery of New HIV‐CA Binding Fragments. ChemMedChem. 2024. doi:10.1002/cmdc.202400025

BibTeX
@article{Lang2024,
  author = {Lang, Stuart and Fletcher, Daniel A and Petit, Alain-Pierre and Luise, Nicola and Fyfe, Paul and Zuccotto, Fabio and Porter, David and Hope, Anthony and Bellany, Fiona and Kerr, Catrina and Mackenzie, Claire J and Wyatt, Paul G and Gray, David W},
  title = {Application of an NMR/Crystallography Fragment Screening Platform for the Assessment and Rapid Discovery of New HIV‐CA Binding Fragments},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400025}
}
Kostenlos starten →